Novo Nordisk's Wegovy pill made DKK 5.39bn in three months while US injectable sales fell 13%. New customers or the same ones switching?
The short version
Novo Nordisk (NVO) reported on Wednesday and raised its outlook for the third time this year. Shares rose more than 6% in early trading.
The headline number: the Wegovy pill generated DKK 5.39 billion, about $810 million, in the third quarter. That is up 53% on the previous quarter and well above the roughly DKK 4.62 billion expected.
But look at the line underneath it. US sales of the injectable version fell 13% at constant exchange rates over the same period.
Combined US Wegovy sales still rose 21%, so the franchise grew. The question is how much of the pill's revenue is genuinely new, and how much is existing customers moving from one format to another.
The rest of the quarter:
- 💵 Sales: DKK 79.2 billion, up 4% at constant exchange rates, against about DKK 73.6 billion expected.
- 📊 Adjusted operating profit: DKK 31.72 billion, up 27%, against about DKK 28.39 billion expected.
- 📉 Reported operating profit fell 9%, on DKK 8.7 billion of non-cash impairment charges.
- 🌍 The pill is now available in eight markets, including the UAE, where it launched in June.
This article is about financial results. It contains no medical information and is not medical advice. Anyone with questions about medication should speak to their own doctor.
People are searching:
- "Novo Nordisk results"
- "NVO stock"
- "Wegovy pill sales"
- "Novo Nordisk guidance 2026"
- "Novo Nordisk vs Eli Lilly"
- "obesity drug market"
- "Novo Nordisk share price"
- "pharma stocks 2026"
Explore global stocks and ETFs from $1 on Nemo.money, with zero commission, and uninvested cash earns 6% AER interest, paid daily in USD.
What Novo Nordisk reported
- 💵 Sales: DKK 79,195 million, up 6% in kroner and 4% at constant exchange rates, against about DKK 73.6 billion expected.
- 📊 Adjusted operating profit: DKK 31,720 million, up 27% at constant exchange rates, against about DKK 28.39 billion expected.
- 📉 Reported operating profit: down 9% at constant exchange rates, on DKK 8.7 billion of non-cash impairment charges.
- 💊 Wegovy pill sales: DKK 5,394 million, up 53% on the previous quarter.
- 🇺🇸 US pill sales: DKK 4.18 billion. International: DKK 1.22 billion.
- 📈 Guidance raised for the third time this year.
On the impairments: the DKK 8.7 billion comprised roughly DKK 4.6 billion related to a pipeline asset and DKK 4.1 billion from right-sizing the manufacturing network. Those are accounting charges rather than cash leaving the business, which is why reported and adjusted profit point in opposite directions.
On the comparison: last year's third quarter included DKK 9 billion of company-wide transformation costs, which makes this year's 27% adjusted growth flattering by comparison. The company notes this itself.
The guidance, and why a third raise matters
Novo now expects 2026 adjusted sales and adjusted operating profit between +2% and -2% at constant exchange rates.
That has moved twice already. The earlier forecast was a decline of between 0% and 6%, itself an improvement on a prior cut.
Three upgrades in one year tells you something about where the company started. This is a business that spent the year revising expectations downward and is now revising them back up. The direction has changed; the level has not yet recovered.
The company attributes the improvement to higher expectations for GLP-1 product sales in both the US and international markets.
New customers, or the same ones switching?
This is the question the quarter raises, and it is a genuinely useful one to understand.
The two figures sit side by side:
- 💊 Pill sales: DKK 5.39 billion, up 53% on the previous quarter.
- 💉 US injectable sales: down 13% at constant exchange rates.
- ➕ Combined US Wegovy sales: up 21%.
So the franchise grew. That much is clear. What is less clear is the composition.
Cannibalisation is the term for this, and it is not automatically a bad thing. When a company launches a new version of something, some buyers of the old version switch. Three outcomes are possible:
- 🟢 Mostly new demand. The product reaches people the old format did not, and total revenue grows substantially.
- 🟡 A mix. Some switching, some genuinely new customers. Revenue grows, but by less than the new product's sales suggest.
- 🔴 Mostly switching. The company replaces its own revenue at a different price point, and the headline number flatters what actually happened.
The combined 21% growth tells you it is not the third case. Something real is being added. But a 53% quarterly jump in one format alongside a 13% decline in another is not simply additive, and treating it that way overstates the growth.
One company figure that bears on this: Novo estimates the pill accounts for roughly 80% of new-to-brand prescriptions in the US. That is the company's own estimate, and it points toward new customers rather than switching, though new-to-brand does not distinguish between people new to the category and people arriving from elsewhere.
The habit worth stealing: when a company launches a new version of an existing product, look for what happened to the old one. The combined figure is the honest one.
It is the same discipline we applied at AMD, where data centre revenue nearly doubled while gaming fell 40%, and at Intel, where a headline foundry figure contained mostly internal revenue. The segment table is where the real answer sits.
How this sits beside our other pharma coverage
Four posts, four different financial questions, all from the same sector this year.
- 💊 Eli Lilly: volume up 53%, realised prices down 15%, revenue up 39%. Growth that survived falling prices, which is the most durable kind there is.
- 🧪 Moderna and Oruka: one trial succeeded and the stock fell 18%, another succeeded and rose 12%. Expectations, not outcomes, moved both.
- 🥊 The obesity treatment market, and who was winning earlier this year. Useful background on how Novo's position has shifted.
- 📈 The wider investing theme these products created, including the companies affected indirectly.
Read together, they make one point. Pharmaceutical results are unusually easy to misread from a headline, because the interesting information is almost always in the composition: volume against price, one format against another, what was expected against what arrived.
This quarter is simply another version of that. A large number for one product, a decline in another, and a combined figure that tells you more than either.
Two profit figures, opposite directions
Adjusted operating profit rose 27%. Reported operating profit fell 9%. Same quarter.
The gap is DKK 8.7 billion of non-cash impairment charges, split between a pipeline asset and right-sizing the manufacturing network. Neither involves cash leaving the business this quarter.
This is now the sixth company in two weeks where the two measures disagreed: Alphabet, Amazon, Intel, Xerox, Mondelez and now Novo Nordisk.
It is not an exception. It is how large companies report, and the habit of checking what sits between the two is one of the most useful things an investor can build.
What could go wrong
- 🔄 The switching question is unresolved. A 53% jump in one format alongside a 13% decline in another means the growth is less additive than the headline implies.
- 📉 The comparison base was favourable. Last year's quarter carried DKK 9 billion of transformation costs, which flatters the 27% adjusted growth figure.
- 🏷️ Guidance is still around flat. Three upgrades this year have moved the range to +2% to -2%. That is a recovery in direction, not yet in level.
- 🥊 Competition is intensifying. A rival oral product is winning a growing share of new prescriptions, and the company is explicitly trying to regain ground it lost.
- 💱 Currency is doing real work. Sales rose 6% in kroner and 4% at constant exchange rates, so part of the reported growth is exchange rates rather than volume.
- 🧾 And the impairments are real information, even though they are non-cash. A company does not write down pipeline assets for no reason.
NVO is an example to research, not a recommendation.
What should investors take from this?
When a company launches a new version of something, find out what happened to the old version.
Novo's pill made $810 million in a quarter, which is a genuinely impressive launch. Its injectable sales in the same market fell 13%. The combined figure, up 21%, is the one that describes what actually happened to the business.
Three habits:
- 🔍 Read the whole product line, not the fastest-growing part of it.
- ⚖️ Check the comparison base. A 27% increase against a quarter that carried DKK 9 billion of one-off costs is not the same as 27% against a normal one.
- 🧺 And remember the index route. Large pharmaceutical companies sit inside broad funds, so an index tracker holds several of them without you choosing any.
Research healthcare stocks on Nemo.money
- From $1. Fractional investing, in research-sized amounts.
- Zero commission on US stocks and ETFs.
- Nemes: curated themed collections to start from.
- 6% AER interest on uninvested cash, paid daily in USD.
FAQs
What did Novo Nordisk report for Q3 2026? Sales of DKK 79.2 billion, up 4% at constant exchange rates and ahead of expectations, with adjusted operating profit of DKK 31.72 billion, up 27%. Reported operating profit fell 9% on DKK 8.7 billion of non-cash impairment charges. The company raised its full-year outlook for the third time this year.
How much did the Wegovy pill sell? DKK 5,394 million, approximately $810 million, up 53% on the previous quarter and above the roughly DKK 4.62 billion expected. US sales were DKK 4.18 billion and international sales DKK 1.22 billion.
Why did injectable sales fall? US sales of the injectable version fell 13% at constant exchange rates while pill sales grew. Combined US Wegovy sales rose 21%. Novo has not published a breakdown of how much of the pill's revenue comes from new customers rather than existing ones switching format.
What is Novo Nordisk's guidance? Adjusted sales and adjusted operating profit growth of between +2% and -2% at constant exchange rates for 2026, raised from a previous range of 0% to a 6% decline. This was the third upgrade of the year.
Can I invest in Novo Nordisk from the UAE? Novo Nordisk trades in the US as an American Depositary Receipt under the ticker NVO, alongside its Copenhagen listing. On Nemo.money you can research and invest in US-listed stocks and ETFs from $1 with zero commission, with uninvested cash earning 6% AER interest, paid daily in USD. NVO is an example to research, not a recommendation. Your capital is at risk.
Nemo = Never Miss Out.
Stay informed. Stay ahead.
#NovoNordisk #NVO #Pharma #Earnings #Investing #NemoMoney
Terms and conditions apply. This is not investment advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.
